Business Wire

New Safety Data on treatment with COPAXONE® (glatiramer acetate) of Breastfeeding Mothers who Live with Relapsing Multiple Sclerosis

Share

Teva Pharmaceuticals Europe BV, a European affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and St. Josef Hospital – Katholisches Klinikum Bochum (Bochum, Germany), presented today at ECTRIMS congress new analyses of the COBRA study, a real-world evidence study on the safety of COPAXONE® (glatiramer acetate or GA) used by mothers with multiple sclerosis (MS) during pregnancy and breastfeeding.

The new analysis of COBRA study, which currently represents the largest dataset of child outcomes breastfed by mothers treated with GA, assessed 99 mothers with MS and their infants. It concluded that no evidence was found to suggest that infants were adversely affected by maternal exposure to GA during pregnancy and breastfeeding with regard to hospitalisations and antibiotic treatments, developmental delay, or growth in the first 18 months of life1.

Professor Kerstin Hellwig, Principal Study Investigator, Department of Neurology, St. Josef Hospital, Ruhr University Bochum, Germany noted:

“Our new analysis, which included 50 offspring in the GA group and 50 in a control group (offspring of mothers with MS not treated with any disease-modifying treatment during pregnancy and breastfeeding), is an important contribution to the significant unmet medical need. There is historically limited clinical safety data for infants who are breastfed by mothers undergoing treatment for MS including during the pregnancy period. We found no evidence that GA exposure was associated with developmental delay, body growth issues or increased hospitalisation and antibiotic use in group of infants from the GA cohort in comparison with controls.

“Half of all MS pregnancies are unplanned, so a woman is on average exposed to disease modifying therapies (DMTs) in the first 30 days of her child’s development until she discovers her pregnancy and the treatment can be discontinued. While re-staring DMT during breastfeeding, a mother has concerns whether her exposure to DMT during pregnancy and breastfeeding may harm her child. Our new analyses of the COBRA study provide data that cumulative maternal exposure to GA during pregnancy and breastfeeding did not adversely affect the babies regarding the parameters studied within the first 18 months after birth”

The COBRA study used data from the German Multiple Sclerosis and Pregnancy Registry (DMSKW) from 2011 to 2020. Patients were eligible for the study if they were diagnosed with relapsing MS (RMS), gave a live birth, were breastfeeding under GA treatment (COPAXONE® 20 or 40 mg/mL) or breastfeeding under no DMT treatment.

Danilo Lembo M.D. VP Medical Europe, Teva Pharmaceuticals comments: “The onset of multiple sclerosis (MS) occurs in women between the ages of 20 and 40 years old; therefore, MS affects women during a key moment in their lives when they’re thinking of having children. This is one of the reasons why family planning, is such an important aspect of MS care in women. Our mission at Teva is to improve the lives of patients, supporting them with important medicines throughout life’s stages, and during family planning in particular.”

The data presentation follows extensive ongoing study of COPAXONE® in a variety of real-world settings that seek to improve treatment decision making. Modern approaches in the care of women with MS after child birth nowadays include that physicians inform them about the benefits of breastfeeding for both the mother with MS and her offspring; encourage the mother to breastfeed if possible; and finally support the patient and her decision. ”

References

  1. A. Ciplea et. Al, Safety analysis of offspring breastfed by mothers on glatiramer acetate therapy for relapsing multiple sclerosis; presented at EAN 2021.
  2. Saneea Almas, Jesse Vance, Teresa Baker, and Thomas Hale, Management of Multiple Sclerosis in the Breastfeeding Mother, Multiple Sclerosis International Volume 2016, Article ID 6527458, http://dx.doi.org/10.1155/2016/6527458
  3. Pakpoor J, Disanto G, Lacey MV, Hellwig K, Giovannoni G, Ramagopalan, Breastfeeding and multiple sclerosis relapses: a meta-analysis. SVJ Neurol. 2012 Oct; 259(10):2246-8.

About the Study

“Real-world safety of Copaxone in Offspring of Breastfeeding and Treated Relapsing Multiple Sclerosis (RMS) pAtients” (COBRA study) is a retrospective data analysis using data of the German Multiple Sclerosis and Pregnancy Registry. In new subgroup analyses, 50 offspring from the glatiramer acetate (GA) cohort (49 pregnancies; 49 women) and 50 from the control (50 pregnancies; 50 women) were included. Maternal demographics and RMS prognostic factors were descriptively comparable between cohorts. “Cumulative” maternal GA-exposure was higher in the GA cohort vs control, because 100% of offspring’s mothers received GA also at some point during pregnancy (vs 26%).

Safety outcomes in ≤18 months of postpartum follow up showed similar results between cohorts, offspring frequency and incidence of hospitalisations. Annualized number of hospitalisations was 0.22 [95% confidence interval {CI}=0.09–0.35] in the GA cohort vs the control (0.26 [95% CI=0.12–0.40]). Frequency and incidence of antibiotic use were similar between cohorts. Growth parameters (body weight, body length and head circumference) were also comparable between cohorts at birth as well as at each of the other five time points studied. Paediatrician check-ups until 12 months identified 2 offspring with developmental delays; all in the control cohort (4%, n=50; [95% CI=0.49–13.71]).

About COPAXONE®

COPAXONE® (glatiramer acetate injection) is indicated for the treatment of patients with relapsing forms of multiple sclerosis. The most common side effects of COPAXONE® are redness, pain, swelling, itching, or a lump at the site of injection, flushing, rash, shortness of breath, and chest pain. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Copaxone therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.

www.CopaxonePrescribingInformation.com. For hardcopy releases, please see enclosed full prescribing information. The COPAXONE® brand is approved in more than 50 countries worldwide, including the United States, Russia, Canada, Mexico, Australia, Israel, and all European countries.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products. Learn more at www.tevapharm.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance.

Important factors that could cause or contribute to such differences include risks relating to the commercial success of COPAXONE®; our ability to successfully compete in the marketplace, including our ability to develop and commercialize biopharmaceutical products, competition for our specialty products, including AUSTEDO®, AJOVY® and COPAXONE®; our ability to achieve expected results from investments in our product pipeline, our ability to develop and commercialize additional pharmaceutical products, and the effectiveness of our patents and other measures to protect our intellectual property rights; our substantial indebtedness; our business and operations in general, including uncertainty regarding the COVID-19 pandemic and its impact on our business, financial condition, operations, cash flows, and liquidity and on the economy in general, our ability to successfully execute and maintain the activities and efforts related to the measures we have taken or may take in response to the COVID-19 pandemic and associated costs therewith, costs and delays resulting from the extensive pharmaceutical regulation to which we are subject or delays in governmental processing time due to travel and work restrictions caused by the COVID-19 pandemic; compliance, regulatory and litigation matters, including failure to comply with complex legal and regulatory environments; other financial and economic risks; and other factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2020, including in the section captioned “Risk Factors.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Enquiries
Fiona Cohen, Teva Europe
+ 31 6 2008 2545
Fiona.cohen@tevaeu.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

X-Chem Acquires ComInnex25.10.2021 21:00:00 EEST | Press release

X-Chem, the pioneer of DNA-encoded library (DEL) technology and recognized leader in generating actionable results to drive small molecule drug discovery, today announced the acquisition of ComInnex, a leading European provider of synthetic chemistry services and novel chemical technologies to support early-stage drug discovery. With demand for high-quality discovery services increasing across the world, this complementary pairing of a North American leader in DEL and medicinal chemistry with a European leader in synthetic chemistry and custom DEL services delivers the capacity, footprint and expertise to better serve the demands of customers in a global market. “As a united company, with an increased global presence, we are positioned to meet the increasing demand for innovative chemistry solutions and high-quality discovery services worldwide,” noted Matt Clark, Ph.D., CEO of X-Chem. “The acquisition of ComInnex further extends X-Chem’s expertise and scale of DEL services to help bio

European Commission Selects Humanigen’s Lenzilumab as One of the 10 Most Promising Treatments for COVID-1925.10.2021 17:30:00 EEST | Press release

Humanigen, Inc. (Nasdaq: HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab, today announced the European Commission identified lenzilumab as one of the “10 most promising treatments for COVID-19” in a report and press release issued on October 22, 2021.1,2 “We are gratified the European Commission has recognized the potential of lenzilumab to offer an important treatment option for patients hospitalized with COVID-19,” said Cameron Durrant, MD, Chairman and CEO, Humanigen. “We look forward to continuing our discussions with colleagues at the European Medicines Agency to advance our efforts to submit a marketing authorization application for lenzilumab in COVID-19. We are also progressing with our early access program, under compassionate use, where allowed by regulations in some European countries and the United States.” *Lenzilumab is not authorized, or approved

Ferring Presents Award-Winning, Real-World Outcomes Analysis for Investigational Microbiota-Based Live Biotherapeutic, RBX2660, at ACG 202125.10.2021 15:00:00 EEST | Press release

Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today announced the results of two key retrospective analyses at the American College of Gastroenterology 2021 annual congress. One analysis evaluated the safety and efficacy of investigational RBX2660 among a broad cohort of CDI patients with comorbidities commonly found in patients with CDI, and was recognized with a Presidential Poster Award for high-quality, novel, unique and interesting research. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211025005099/en/ Ferring Fact Sheet While the eligibility criteria in prospective clinical trials often are narrowly defined to include patients diagnosed with only CDI, this analysis allowed researchers to evaluate the impact of RBX2660 in a patient population that is more reflective of a real-world setting. In the analysis, 94 participants with comorbid conditions commonly found in people with recurrent CDI (rCDI) were trea

Study Finds Overwhelming Evidence That Color Blindness Hinders Learning in School, Reports EnChroma25.10.2021 15:00:00 EEST | Press release

EnChroma – creators of glasses for color blindness – today released the results of a landmark study that clearly demonstrates the negative effect color blindness has on learning for millions of students. The data strongly indicates that schools are failing to identify color blind students and that parents, educators and legislators need to better support these students. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211025005173/en/ Standard Color Vision and Color Blind View @EnChroma In early 2020, nearly 1,000 color blind people, including the parents of color blind children, shared their opinions about how Color Vision Deficiency (CVD) affected their educational experiences. Seventy-eight percent said they were often frustrated or confused by colors in school assignments and activities. One in three say color blindness affected their confidence in school, and 30% felt like they might be a “slow learner” before discovering

Rockefeller Capital Management to Open First International Office in London with the Formation of Rockefeller Asset Management International25.10.2021 15:00:00 EEST | Press release

Rockefeller Asset Management (RAM), a division of Rockefeller Capital Management, with a long track record of investing in global equities and ESG investing has announced the formation of Rockefeller Asset Management International, to expand its European market presence. The initial plans for expansion include opening an office in London, to better serve clients across the UK, Europe, and Asia. “Our Asset Management business has generated real momentum across Europe and we are excited to continue to serve our international clients with a full suite of sustainable investment products and a growing local presence,” said Greg Fleming, CEO and President of Rockefeller Capital Management. RAM, which was recently awarded the 2021 Principles for Responsible Investing (PRI) award for “ESG incorporation initiative of the year,” has seen strong growth in Europe. Over the last two years, the business, which surpassed $2.5 billion in assets from European investors, launched a UCITS ICAV, an Irelan

CAPRISA and Evotec Launch New Project to Fast-Track New Technology for HIV Prevention25.10.2021 14:53:00 EEST | Press release

Today, at a side meeting during the AU-EU Ministerial Summit in Kigali, Rwanda, Prof Salim Abdool Karim, Director of CAPRISA, announced a collaboration with a leading life science company Evotec for the designing and development of CAP256, a broadly neutralizing antibody against HIV. The project is a major expansion of the development of an antibody originally developed jointly by CAPRISA and the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases of the US NIH. This new project is a major boost for the CAP256 antibody as a potential tool in the fight against HIV in Africa and showcases the potential of African researchers to fight the continent’s high-burden diseases. The principal aim of the new joint project is to change the course of the HIV epidemic in Africa, which has 70% of the global HIV burden. CAP256, isolated from a South African woman by CAPRISA and the VRC, has demonstrated a good safety profile in Phase I studies. The next step is t

Everbridge Awarded Contract to Power Countrywide Public Warning System in The Netherlands25.10.2021 14:30:00 EEST | Press release

Everbridge, Inc. (NASDAQ: EVBG), the global leader in critical event management (CEM), today announced that the Netherlands selected the company’s end-to-end countrywide Public Warning solution to help keep its residents and visitors safe and informed in the event of an emergency. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211025005296/en/ Everbridge Awarded Contract to Power Countrywide Public Warning System in The Netherlands (Photo: Business Wire) One of the most densely populated regions in Europe, 17.5 million residents call the Netherlands home, and millions of tourists visit the coastal country each year. Powered by Everbridge, NL-Alert can reach 94 percent of the Dutch population on their mobile phones, along with digital signage at bus, train, tram, and metro stations across the country. The Netherlands will leverage Everbridge’s next-generation, end-to-end Public Warning solution, featuring a unique multi-chann

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom